OptimizeRx Corp. (NASDAQ:OPRX) Receives $13.43 Consensus Target Price from Analysts

Shares of OptimizeRx Corp. (NASDAQ:OPRX) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $13.4286.

A number of research firms have recently weighed in on OPRX. Stephens cut their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 13th. Stifel Nicolaus cut their price objective on OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings lowered OptimizeRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, May 14th. B. Riley Financial cut their price objective on OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 13th. Finally, Roth Mkm cut their price objective on OptimizeRx from $32.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, March 6th.

Institutional Trading of OptimizeRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. CenterBook Partners LP acquired a new stake in OptimizeRx in the third quarter valued at $6,331,000. Wesbanco Bank Inc. acquired a new stake in shares of OptimizeRx during the third quarter worth about $205,000. Principal Financial Group Inc. acquired a new stake in shares of OptimizeRx during the third quarter worth about $386,000. State of Wyoming acquired a new stake in shares of OptimizeRx during the third quarter worth about $448,000. Finally, Strs Ohio acquired a new stake in shares of OptimizeRx during the third quarter worth about $502,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

OptimizeRx Stock Performance

Shares of NASDAQ OPRX opened at $4.94 on Monday. OptimizeRx has a twelve month low of $4.57 and a twelve month high of $22.25. The company has a current ratio of 5.37, a quick ratio of 5.37 and a debt-to-equity ratio of 0.16. The stock has a fifty day simple moving average of $6.25 and a 200-day simple moving average of $10.07. The stock has a market capitalization of $92.67 million, a PE ratio of 14.11 and a beta of 1.19.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.The business had revenue of $19.84 million during the quarter, compared to analysts’ expectations of $18.74 million. On average, equities analysts forecast that OptimizeRx will post 0.5 earnings per share for the current year.

OptimizeRx announced that its board has authorized a share repurchase program on Thursday, March 5th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s management believes its shares are undervalued.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.